Laboratory Medicine ›› 2021, Vol. 36 ›› Issue (8): 886-890.DOI: 10.3969/j.issn.1673-8640.2021.08.022
Received:2020-12-14
Online:2021-08-30
Published:2021-08-30
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2021.08.022
| 组别 | 例数 | LTB4R /% | IL-4/（pg/mL） | IL-5/（pg/mL） | IL-13/（pg/mL） |
|---|---|---|---|---|---|
| 哮喘组 | 100 | 25.02±4.08 | 34.16±4.95 | 3.85±0.79 | 399.38±105.18 |
| 喘支组 | 32 | 20.20±4.70 | 24.93±5.62 | 2.98±1.53 | 256.41±189.91 |
| t值 | 5.60 | 8.88 | 3.09 | 4.06 | |
| P值 | <0.01 | <0.01 | <0.01 | <0.01 |
| 组别 | 例数 | LTB4R /% | IL-4/（pg/mL） | IL-5/（pg/mL） | IL-13/（pg/mL） |
|---|---|---|---|---|---|
| 哮喘组 | 100 | 25.02±4.08 | 34.16±4.95 | 3.85±0.79 | 399.38±105.18 |
| 喘支组 | 32 | 20.20±4.70 | 24.93±5.62 | 2.98±1.53 | 256.41±189.91 |
| t值 | 5.60 | 8.88 | 3.09 | 4.06 | |
| P值 | <0.01 | <0.01 | <0.01 | <0.01 |
| 项目 | AUC（95%CI） | 最佳临界值 | 敏感性/% | 特异性/% | 准确性/% |
|---|---|---|---|---|---|
| LTB4R | 0.784（0.710~0.857） | 29.46% | 76.54 | 70.34 | 46.88 |
| IL-4 | 0.787（0.887~0.965） | 37.83 pg/mL | 72.27 | 80.29 | 50.56 |
| IL-5 | 0.688（0.605~0.771） | 4.35 pg/mL | 68.21 | 62.46 | 30.67 |
| IL-13 | 0.739（0.661~0.818） | 413.58 pg/mL | 76.87 | 60.34 | 37.21 |
| 风险评分模型 | 0.926（0.887~0.965） | 468.18 | 88.18 | 76.50 | 64.68 |
| 项目 | AUC（95%CI） | 最佳临界值 | 敏感性/% | 特异性/% | 准确性/% |
|---|---|---|---|---|---|
| LTB4R | 0.784（0.710~0.857） | 29.46% | 76.54 | 70.34 | 46.88 |
| IL-4 | 0.787（0.887~0.965） | 37.83 pg/mL | 72.27 | 80.29 | 50.56 |
| IL-5 | 0.688（0.605~0.771） | 4.35 pg/mL | 68.21 | 62.46 | 30.67 |
| IL-13 | 0.739（0.661~0.818） | 413.58 pg/mL | 76.87 | 60.34 | 37.21 |
| 风险评分模型 | 0.926（0.887~0.965） | 468.18 | 88.18 | 76.50 | 64.68 |
| 组别 | 例数 | LTB4R /% | IL-4/（pg/mL） | IL-5/（pg/mL） | IL-13/（pg/mL） |
|---|---|---|---|---|---|
| 轻症组 | 70 | 23.99±4.42 | 31.95±8.95 | 3.59±1.34 | 150.86±155.81 |
| 重症组 | 30 | 27.41±4.53 | 39.30±9.29 | 4.77±1.64 | 545.72±184.33 |
| t值 | 3.52 | 3.72 | 3.77 | 10.98 | |
| P值 | <0.01 | <0.01 | <0.01 | <0.01 |
| 组别 | 例数 | LTB4R /% | IL-4/（pg/mL） | IL-5/（pg/mL） | IL-13/（pg/mL） |
|---|---|---|---|---|---|
| 轻症组 | 70 | 23.99±4.42 | 31.95±8.95 | 3.59±1.34 | 150.86±155.81 |
| 重症组 | 30 | 27.41±4.53 | 39.30±9.29 | 4.77±1.64 | 545.72±184.33 |
| t值 | 3.52 | 3.72 | 3.77 | 10.98 | |
| P值 | <0.01 | <0.01 | <0.01 | <0.01 |
| 项目 | AUC（95%CI） | 最佳临界值 | 敏感性/% | 特异性/% | 准确性/% |
|---|---|---|---|---|---|
| LTB4R | 0.677（0.565~0.788） | 33.52% | 76.52 | 50.07 | 26.59 |
| IL-4 | 0.700（0.592~0.807） | 41.27 pg/mL | 70.91 | 60.38 | 31.29 |
| IL-5 | 0.689（0.573~0.804） | 4.97 pg/mL | 70.56 | 57.77 | 28.33 |
| IL-13 | 0.801（0.708~0.895） | 556.07 pg/mL | 87.88 | 57.38 | 45.26 |
| 风险评分模型 | 0.926（0.787~0.963） | 643.61 | 90.24 | 65.42 | 50.66 |
| 项目 | AUC（95%CI） | 最佳临界值 | 敏感性/% | 特异性/% | 准确性/% |
|---|---|---|---|---|---|
| LTB4R | 0.677（0.565~0.788） | 33.52% | 76.52 | 50.07 | 26.59 |
| IL-4 | 0.700（0.592~0.807） | 41.27 pg/mL | 70.91 | 60.38 | 31.29 |
| IL-5 | 0.689（0.573~0.804） | 4.97 pg/mL | 70.56 | 57.77 | 28.33 |
| IL-13 | 0.801（0.708~0.895） | 556.07 pg/mL | 87.88 | 57.38 | 45.26 |
| 风险评分模型 | 0.926（0.787~0.963） | 643.61 | 90.24 | 65.42 | 50.66 |
| [1] |
HASSOUN D, MOUI A, COLAS L, et al. Update in severe asthma physiopathology and treatments[J]. Rev Med Interne, 2019, 40(8):508-516.
DOI URL |
| [2] |
GEAY L E K, SLY P D. Update in asthma 2017[J]. Am J Respir Crit Care Med, 2018, 197(9):1108-1115.
DOI URL |
| [3] |
SULLIVAN P W, GHUSHCHYAN V, NAVARATNAM P, et al. The national burden of poorly controlled asthma,school absence and parental work loss among school-aged children in the United States[J]. J Asthma, 2018, 55(6):659-667.
DOI URL |
| [4] |
WENZEL S E. Emergence of biomolecular pathways to define novel asthma phenotypes. Type-2 immunity and beyond[J]. Am J Respir Cell Mol Biol, 2016, 55(1):1-4.
DOI URL |
| [5] |
LEE A J, RO M, KIM J H. Leukotriene B4 receptor 2 is critical for the synjournal of vascular endothelial growth factor in allergen-stimulated mast cells[J]. J Immunol, 2016, 197(6):2069-2078.
DOI PMID |
| [6] | 中华医学会儿科学分会呼吸学组, 《中华儿科杂志》编辑委员会. 儿童支气管哮喘诊断与防治指南(2016年版)[J]. 中华儿科杂志, 2016, 54(3):167-181. |
| [7] | 范永琛. 小儿哮喘与“喘息性支气管炎”的区别[J]. 中华儿科杂志, 2006, 44(1):68-70. |
| [8] |
KWON S Y, KIM J H. Role of leukotriene B4 receptor-2 in mast cells in allergic airway inflammation[J]. Int J Mol Sci, 2019, 20(12):2897.
DOI URL |
| [9] |
GELFAND E W. Importance of the leukotriene B4-BLT1 and LTB4-BLT2 pathways in asthma[J]. Semin Immunol, 2017, 33:44-51.
DOI URL |
| [10] |
COSMI L, MAGGI L, MAZZONI A, et al. Biologicals targeting type 2 immunity:lessons learned from asthma,chronic urticaria and atopic dermatitis[J]. Eur J Immunol, 2019, 49(9):1334-1343.
DOI URL |
| [11] | 王执勇, 李树青, 钱秀玲. 孟鲁司特治疗呼吸道合胞病毒毛细支气管炎症状及反复喘息疗效研究[J]. 中国全科医学, 2020, 23(8):929-934. |
| [12] |
VALE K. Targeting the JAK-STAT pathway in the treatment of 'Th2-high' severe asthma[J]. Future Med Chem, 2016, 8(4):405-419.
DOI URL |
| [13] | 董天津, 谭华清, 修青永. 支气管哮喘患儿血清CCL3、CCL5检测水平与FeNO及肺功能的关系[J]. 临床肺科杂志, 2020, 25(3):381-384. |
| [14] | 白鹏, 韩桂珍, 鲁丽. 支气管哮喘患儿痰液中CXCR2、CCR1、CCL3、CCL2表达及与肺功能和气道炎症的关系[J]. 河北医药, 2019, 41(23):3555-3558. |
| [15] | 董欢, 王瑞平, 侯博, 等. 支气管哮喘患儿血清CCL2表达及与巨噬细胞极化状态的关系[J]. 临床肺科杂志, 2019, 24(9):1651-1655. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
